Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
== Human uses == Castor oil has been used orally to relieve constipation or to evacuate the bowel before intestinal surgery. The laxative effect of castor oil is attributed to ricinoleic acid, which is produced by hydrolysis in the small intestine. Use of castor oil for simple constipation is medically discouraged because it may cause violent diarrhea.
Unlike most arbuscular mycorrhizal fungi, EcM fungi reproduce sexually and produce visible fruiting bodies in a wide variety of forms. The fruiting body, or sporocarp, can be thought of as an extension of the extraradical hyphae. Its cell walls and spores are typically composed of complex carbohydrates, and often incorporate a great deal of nitrogen. Many EcM fungi can only form fruiting bodies and complete their life cycles by participating in an EcM relationship. The fruit bodies of many species take on classic, well-recognized shapes such as epigeous mushrooms and hypogeous truffles. Most of these produce microscopic propagules of about 10 μm that can disperse over large distances by way of various vectors, ranging from wind to mycophagous animals. It has been suggested that animals are drawn to hypogeous fruiting bodies because they are rich in nutrients such as nitrogen, phosphorus, minerals and vitamins. However, others argue that the specific nutrients are less important than the availability of food at specific times of the year. Surveys of fruiting bodies have been used to assess community composition and richness in many studies. However, this method is imperfect as fruiting bodies do not last long and can be hard to detect.
The original Counter-Strike has been played in competitive tournaments since 2000, with the first major event taking place at the Cyberathlete Professional League (CPL) Winter Championship in 2001. The CPL announced a transition from Quake III Arena to Counter-Strike for the Winter Championship. Prior to this, the 2000 Babbage's event featured a Counter-Strike competition sponsored by Kärna, the parent company of Razer, offering a $15,000 prize pool. However, Kärna experienced financial difficulties, leading to delays in prize payouts. On March 14, 2001, the CPL issued a statement confirming that alternative arrangements would be made if the payments were not received by April 2, 2001.
Support for teens (archive) University of Maryland guide to puberty and adolescence Growing Up Sexually: A World Atlas Pictures and detailed information about breast development during puberty Puberty in females: interactive animation of Tanner stages Puberty in males: interactive animation of Tanner stages
In their second publication on nuclear fission, Hahn and Strassmann used the term Uranspaltung (uranium fission) for the first time, and predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction. This was shown to be the case by Frédéric Joliot and his team in March 1939. Edwin McMillan and Philip Abelson used the cyclotron at the Berkeley Radiation Laboratory to bombard uranium with neutrons, and were able to identify an isotope with a 23-minute half-life that was the daughter of uranium-239, and therefore the real element 93, which they named neptunium. "There goes a Nobel Prize", Hahn remarked. At the KWIC, Kurt Starke independently produced element 93, using only the weak neutron sources available there. Hahn and Strassmann then began researching its chemical properties. They knew that it should decay into the real element 94, which according to the latest version of the liquid drop model of the nucleus propounded by Bohr and John Archibald Wheeler, would be even more fissile than uranium-235, but were unable to detect its radioactive decay. They concluded that it must have an extremely long half-life, perhaps millions of years. Part of the problem was that they still believed that element 94 was a platinoid, which confounded their attempts at chemical separation.
Sources: en.wikipedia.org
Flexibility is improved by stretching. Stretching should only be started when muscles are warm and the body temperature is raised. To be effective while stretching, force applied to the body must be held just beyond a feeling of pain and needs to be held for at least ten seconds. Increasing the range of motion creates good posture and develops proficient performance in everyday activities increasing the length of life and overall health of the individual.
=== Breast cancer === Docetaxel and paclitaxel have comparable efficacy metastatic breast cancer but paclitaxel has less severe side effects. Additionally, it has been noted that docetaxel is prone to cellular drug resistance via a variety of different mechanisms.
=== Straight side chain === The genetic code has been described as a frozen accident and the reasons why there is only one standard amino acid with a straight chain, alanine, could simply be redundancy with valine, leucine and isoleucine. However, straight chained amino acids are reported to form much more stable alpha helices.
==== Congressional proposals ==== The House of Representatives Committee on the Budget, chaired by Rep. Paul Ryan (R), released The Path to Prosperity: Restoring America's Promise and a 2012 budget. The Path focuses on tax reform (lowering income tax rates and reducing tax expenditures or loopholes); spending cuts and controls; and redesign of the Medicare and Medicaid programs. It does not propose significant changes to Social Security. The Bipartisan Policy Center (BPC) evaluated the 2012 Republican budget proposal, noting it had the lowest spending and tax revenue relative to GDP among several alternatives. The Congressional Progressive Caucus (CPC) proposed "The People's Budget" in April 2011, which it claimed would balance the budget by 2021 while maintaining debt as a % GDP under 65%. It proposed reversing most of the Bush tax cuts; higher income tax rates on the wealthy and restoring the estate tax, investing in a jobs program, and reducing defense spending. The BPC evaluated the proposal, noting it had both the highest spending and tax revenue relative to GDP among several alternatives. The CPC also proposed a 2014 budget called "Back to Work." It included short-term stimulus, defense spending cuts, and tax increases. Congressmen Jim Cooper (D-TN) and Steven LaTourette (R-OH) proposed a budget in the House of Representatives in March 2012. While it did not pass the House, it received bi-partisan support, with 17 votes in favor from each party.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.